Development of a drug–disease simulation model for rituximab in follicular non-Hodgkin's lymphoma

AIM: Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphomas (NHL), but the dosing regimen currently used should be optimized. However, the concentration–effect relationship of rituximab has never been described by pharmacokinetic–pharmacodynamic (PK–PD) modell...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ternant, David, Hénin, Emilie, Cartron, Guillaume, Tod, Michel, Paintaud, Gilles, Girard, Pascal
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Blackwell Science Inc 2009
Gaiak:
Pharmacokinetic Dynamic Relationships
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2780281/
https://ncbi.nlm.nih.gov/pubmed/19843059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2009.03494.x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak